| Literature DB >> 36267428 |
Danielle Ireland1, Siqi Zhang2, Veronica Bochenek1, Jui-Hua Hsieh3, Christina Rabeler1, Zane Meyer4,5, Eva-Maria S Collins1,6,7,8,9.
Abstract
Organophosphorus pesticides (OPs) are a chemically diverse class of commonly used insecticides. Epidemiological studies suggest that low dose chronic prenatal and infant exposures can lead to life-long neurological damage and behavioral disorders. While inhibition of acetylcholinesterase (AChE) is the shared mechanism of acute OP neurotoxicity, OP-induced developmental neurotoxicity (DNT) can occur independently and/or in the absence of significant AChE inhibition, implying that OPs affect alternative targets. Moreover, different OPs can cause different adverse outcomes, suggesting that different OPs act through different mechanisms. These findings emphasize the importance of comparative studies of OP toxicity. Freshwater planarians are an invertebrate system that uniquely allows for automated, rapid and inexpensive testing of adult and developing organisms in parallel to differentiate neurotoxicity from DNT. Effects found only in regenerating planarians would be indicative of DNT, whereas shared effects may represent neurotoxicity. We leverage this unique feature of planarians to investigate potential differential effects of OPs on the adult and developing brain by performing a comparative screen to test 7 OPs (acephate, chlorpyrifos, dichlorvos, diazinon, malathion, parathion and profenofos) across 10 concentrations in quarter-log steps. Neurotoxicity was evaluated using a wide range of quantitative morphological and behavioral readouts. AChE activity was measured using an Ellman assay. The toxicological profiles of the 7 OPs differed across the OPs and between adult and regenerating planarians. Toxicological profiles were not correlated with levels of AChE inhibition. Twenty-two "mechanistic control compounds" known to target pathways suggested in the literature to be affected by OPs (cholinergic neurotransmission, serotonin neurotransmission, endocannabinoid system, cytoskeleton, adenyl cyclase and oxidative stress) and 2 negative controls were also screened. When compared with the mechanistic control compounds, the phenotypic profiles of the different OPs separated into distinct clusters. The phenotypic profiles of adult vs. regenerating planarians exposed to the OPs clustered differently, suggesting some developmental-specific mechanisms. These results further support findings in other systems that OPs cause different adverse outcomes in the (developing) brain and build the foundation for future comparative studies focused on delineating the mechanisms of OP neurotoxicity in planarians.Entities:
Keywords: Organophosphorus (OP) pesticides; behavior; benchmark concentration; developmental neurotoxicity; new approach method; planarian
Year: 2022 PMID: 36267428 PMCID: PMC9578561 DOI: 10.3389/ftox.2022.948455
Source DB: PubMed Journal: Front Toxicol ISSN: 2673-3080
Chemical overview.
| Chemical name | CAS | DTXSID | Class/mode of action | Concentration range | Supplier | Purity (%) |
|---|---|---|---|---|---|---|
| Acephate | 30560-19-1 | DTXSID8023846 | OP | 1.78–316 | Sigma-Aldrich | 98 |
| Chlorpyrifos | 2921-88-2 | DTXSID4020458 | OP | 0.178–31.6 | Sigma-Aldrich | 100 |
| Diazinon | 333-41-5 | DTXSID9020407 | OP | 0.0316–31.6 | Sigma-Aldrich | 98 |
| Dichlorvos | 62-73-7 | DTXSID5020449 | OP | 0.00562–3.16 | Sigma-Aldrich | 98 |
| Malathion | 121-75-5 | DTXSID4020791 | OP | 0.316–56.2 | MP Biomedicals | 96 |
| Parathion | 56-38-2 | DTXSID7021100 | OP | 0.178–31.6 | Sigma-Aldrich | 100 |
| Profenofos | 41198-08-7 | DTXSID3032464 | OP | 0.0562–10 | Chem Service | 97 |
| Aldicarb | 116-06-3 | DTXSID0039223 | Carbamate AChE inhibitor | 3.16–316 | Sigma-Aldrich | 98 |
| Physostigmine | 57-47-6 | DTXSID3023471 | Carbamate AChE inhibitor | 0.1–10 | Sigma-Aldrich | 99 |
| Anatoxin-A | 64285-06-9 | DTXSID50867064 | Nicotinic AChR agonist | 1–100 | Abcam | 98 |
| Nicotine | 54-11-5 | DTXSID1020930 | Nicotinic AChR agonist | 10–1000 | Sigma-Aldrich | 98 |
| Muscarine chloride | 2936-25-6 | DTXSID40861854 | Muscarinic AChR agonist | 1–100 | Sigma-Aldrich | 98 |
| Bethanechol chloride | 590-63-6 | DTXSID2022676 | Muscarinic AChR agonist | 3.16–316 | TCI America | 98 |
| Buspirone hydrochloride | 33386-08-2 | DTXSID1037193 | Serotonin (5-HT) 1 receptor agonist | 1–100 | Sigma-Aldrich | 99 |
| Mianserin hydrochloride | 21535-47-7 | DTXSID30944145 | Serotonin (5-HT) 1 receptor antagonist; Histamine H1-receptor agonist | 1–100 | Sigma-Aldrich | 98 |
| Fluoxetine hydrochloride | 56296-78-7 | DTXSID7020635 | Selective serotonin reuptake inhibitor | 1–100 | Sigma-Aldrich | 98 |
| Sertraline hydrochloride | 79559-97-0 | DTXSID1040243 | Selective serotonin reuptake inhibitor | 1–100 | Sigma-Aldrich | 98 |
| MDL-12,330A | 40297-09-4 | DTXSID10432999 | Adenyl cyclase inhibitor | 1–100 | Sigma-Aldrich | 98 |
| LRE-1 | 1252362-53-0 | NA | Adenyl cyclase inhibitor | 1–100 | Sigma-Aldrich | 98 |
| Colchicine | 64-86-8 | DTXSID5024845 | Disrupts microtubule polymerization | 3.16–316 | Acros Organics | 97 |
| Nocodazole | 31430-18-9 | DTXSID9031800 | Disrupts microtubule polymerization | 0.1–10 nM | Sigma-Aldrich | 98 |
| Cytochalasin D | 22144-77-0 | DTXSID8037099 | Disrupts actin polymerization | 0.316–31.6 | MP Biomedicals | 99 |
| Latrunculin A | 76343-93-6 | DTXSID90893488 | Disrupts actin polymerization | 0.316–31.6 nM | Sigma-Aldrich | 95 |
| Anandamide | 94421-68-8 | DTXSID301017453 | Endocannabinoid | 1–100 | Sigma-Aldrich | 97 |
| WIN 55 212-2 mesylate | 131543-23-2 | DTXSID50424974 | CB-1 receptor agonist | 0.1–10 | Sigma-Aldrich | 98 |
| L-buthionine sulfoxime | 83730-53-4 | DTXSID70894150 | Induces oxidative stress | 0.1–10 mM | Sigma-Aldrich | 97 |
| Rotenone | 83-79-4 | DTXSID6021248 | Induces oxidative stress | 3.16–316 nM | Sigma-Aldrich | 100 |
| L-ascorbic acid | 50-81-7 | DTXSID5020106 | Negative control | 1–100 | Alfa Aesar | 99 |
| D-glucitol | 50-70-4 | DTXSID5023588 | Negative control | 1–100 | Sigma-Aldrich | 99 |
NA: not available.
Unless otherwise stated, concentrations are in µM.
Binary endpoints. The standard deviation (SD) of the vehicle controls and benchmark response (BMR) are compared for each endpoint on day 7 (d7) and day 12 (d12), except for eye regeneration and scrunching which were only evaluated on d7 and d12, respectively.
| Endpoint | Description | Adult | Regenerating | |||
|---|---|---|---|---|---|---|
| SD (%) | BMR (%) | SD (%) | BMR (%) | |||
| Lethality | % dead | d7: 1 | d7: 10 | d7: 0 | d7: 10 | |
| d12: 3 | d12: 20 | d12: 2 | d12: 15 | |||
| Body shape | % individuals with any abnormal body shape | d7: 2 | d7: 20 | d7: 6 | d7: 30 | |
| d12: 6 | d12: 25 | d12: 6 | d12: 25 | |||
| Stickiness | % stuck individuals | d7: 26 | d7: 50 | d7: 18 | d7: 50 | |
| d12: 22 | d12: 50 | d12: 20 | d12: 50 | |||
| Eye regeneration | % individuals with abnormally regenerated eyes | ---- | d7: 12 | d7: 55 | ||
| Scrunching | % non-scrunching planarians | d12: 11 | d12: 25 | d12: 13 | d12: 50 | |
Continuous endpoints. The standard deviation (SD) of the normalized response in the vehicle controls and benchmark response (BMR) are compared for each endpoint on day 7 (d7) and day 12 (d12). Some endpoints can have effects in both the positive and negative directions. In these cases, the BMRs for each direction (increasing (+) or decreasing (-)) are shown.
| Endpoint | Description | Normalization | Adult | Regenerating | ||
|---|---|---|---|---|---|---|
| SD | BMR | SD | BMR | |||
| Speed (dark1-1) | Mean speed (mm/s) in 1st 30 s of 1st dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 58 | d7: 90/35 (+/-) | d7: 37 | d7: 60/35 (+/-) |
| d12: 51 | d12: 85/45 (+/-) | d12: 51 | d12: 90/60 (+/-) | |||
| Speed (dark1-2) | Mean speed (mm/s) in 2nd 30 s of 1st dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 62 | d7: 110/90 (+/-) | d7: 37 | d7: 60/40 (+/-) |
| d12: 54 | d12: 90/45 (+/-) | d12: 54 | d12: 100/60 (+/-) | |||
| Speed (green1) | Mean speed (mm/s) in 1st first 30 s of green cycle | (Responsechemical-Responsevehicle) *100 | d7: 60 | d7: 70/65 (+/-) | d7: 34 | d7: 50/30 (+/-) |
| d12: 49 | d12: 85/45 (+/-) | d12: 51 | d12: 85/60 (+/-) | |||
| Speed (green2) | Mean speed (mm/s) in 2nd 30 s of green cycle | (Responsechemical-Responsevehicle) *100 | d7: 64 | d7: 60/95 (+/-) | d7: 37 | d7: 60/115 (+/-) |
| d12: 57 | d12: 95/60 (+/-) | d12: 55 | d12: 115/65 (+/-) | |||
| Speed (dark2-1) | Mean speed (mm/s) in 1st 30 s of 2nd dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 52 | d7: 50/70 (+/-) | d7: 26 | d7: 35/30 (+/-) |
| d12: 47 | d12: 60/30 (+/-) | d12: 46 | d12: 55/50 (+/-) | |||
| Speed (dark2-2) | Mean speed (mm/s) in 2nd 30 s of 2nd dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 57 | d7: 60/90 (+/-) | d7: 29 | d7: 40/30 (+/-) |
| d12: 53 | d12: 50/55 (+/-) | d12: 48 | d12: 100/45 (+/-) | |||
| Speed (dark2-3) | Mean speed (mm/s) in 3rd 30 s of 2nd dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 57 | d7: 65/75 (+/-) | d7: 32 | d7: 40/30 (+/-) |
| d12: 53 | d12: 65/35 (+/-) | d12: 48 | d12: 90/45(+/-) | |||
| Speed (dark2-4) | Mean speed (mm/s) in 4th 30 s of 2nd dark cycle | (Responsechemical-Responsevehicle) *100 | d7: 57 | d7: 65/90 (+/-) | d7: 33 | d7: 45/30 (+/-) |
| d12: 53 | d12: 80/45 (+/-) | d12: 48 | d12: 95/60 (+/-) | |||
| Speed (blue1) | Mean speed (mm/s) in 1st 30 s of blue cycle | (Responsechemical-Responsevehicle) *100 | d7: 49 | d7: 45/60 (+/-) | d7: 27 | d7: 45/20 (+/-) |
| d12: 49 | d12: 65/55 (+/-) | d12: 47 | d12: 70/45 (+/-) | |||
| Speed (blue2) | Mean speed (mm/s) in 2nd 30 s of blue cycle | (Responsechemical-Responsevehicle) *100 | d7: 47 | d7: 65/75 (+/-) | d7: 33 | d7: 50/45 (+/-) |
| d12: 49 | d12: 60/70 (+/-) | d12: 49 | d12: 80/55 (+/-) | |||
| Resting | Fraction of time spent resting in 2nd dark cycle | (Responsechemical-Responsevehicle)*100 | d7: 40 | d7: 65/40 (+/-) | d7: 31 | d7: 35/60 (+/-) |
| d12: 42 | d12: 45/70 (+/-) | d12: 38 | d12: 50/55 (+/-) | |||
| Phototaxis | Average speed in blue cycle -2nd minute of 2nd dark cycle | (Responsechemical-Responsevehicle)*100 | d7: 27 | d7: 35/45 (+/-) | d7: 19 | d7: 30/20 (+/-) |
| d12: 23 | d12: 30/40 (+/-) | d12: 26 | d12: 35/35 (+/-) | |||
| Wall preference | Fraction of time spent in outer region of well | (Responsechemical/Responsevehicle)*100-100 | d7: 23 | d7: 35 (-) | d7: 32 | d7: 40 (-) |
| d12: 32 | d12: 25 (-) | d12: 32 | d12: 35 (-) | |||
| Locomotor bursts (total) | Sum of locomotor bursts in phototaxis assay | Responsechemical-Responsevehicle | d7: 19 | d7: 11/7 (+/-) | d7: 23 | d7: 18/11 (+/-) |
| d12: 21 | d12: 11/6 (+/-) | d12: 22 | d12: 9/6 (+/-) | |||
| Locomotor bursts (ratio) | # locomotor bursts in blue cycle/# locomotor bursts in 2nd dark cycle | Responsechemical-Responsevehicle | d7: 2.5 | d7: 5.5/3.5 (+/-) | d7: 3 | d7: 5.5/4 (+/-) |
| d12: 3 | d12: 5.5/3.5 (+/-) | d12: 3 | d12: 4.5/3.5 (+/-) | |||
| Thermotaxis | Fraction of time in cold zone | (Responsechemical/Responsevehicle)*100-100 | d12: 22 | d12: 45(-) | d12: 23 | d12: 40 (-) |
| Noxious stimuli (rate) | Rate of change in displacement in response to heat ( | (Responsechemical-Responsevehicle) *100 | d12: 17 | d12: 35/25 (+/-) | d12: 20 | d12: 35/30 (+/-) |
| Noxious stimuli (strength) | Median displacement at end of noxious heat ( | (Responsechemical/Responsevehicle)*100-100 | d12: 45 | d12: 50/65 (+/-) | d12: 48 | d12: 50/65 (+/-) |
OP concentrations tested in Ellman assays.
| Chemical name | Concentrations tested (μM) |
|---|---|
| Acephate | 0.0316, 0.316, 3.16, 31.6, 316 |
| Chlorpyrifos | 0.00316, 0.0316, 0.1, 0.316, 3.16, 10 |
| Diazinon | 0.0001, 0.001, 0.01, 0.0316, 0.178, 0.316, 3.16 |
| Dichlorvos | 0.0001, 0.001, 0.01, 0.0316, 0.1, 0.316, 3.16 |
| Malathion | 0.0316, 0.316, 3.16, 10, 56.2, 100 |
| Parathion | 0.000316, 0.00316, 0.0316, 0.1, 0.316, 3.16 |
| Profenofos | 0.000316, 0.00316, 0.01, 0.0316, 0.316, 1.78 |
FIGURE 1Comparison of OP toxicity. Heatmaps comparing the benchmark concentrations (BMCs) for the OPs in adult (A) and regenerating (B) planarians. The first row shows the highest tested concentration. For outcome measures that can have effects in both directions, the BMCs are separated by either the positive (+) or negative (-) direction. For readability, speed endpoints that were inactive in both adult and regenerating planarians are not shown. LB: locomotor bursts; NS: noxious stimuli.
FIGURE 2Connections between individual OPs and classes of endpoints. Interaction of the seven OPs with the different endpoint classes for (A) adult and (B) regenerating planarians. Connections were made if the OP caused a hit at either day 7 or 12 at any tested concentration. Effects on speed in the dark period, resting, or locomotor bursts were combined into the “Motility” category. Speed(B): speed in the blue period, Speed(G): speed in the green period, PT: Phototaxis, NS: noxious stimuli. For endpoints that had effects in both directions, the BMCs are separated by either the positive (+) or negative (-) direction.
FIGURE 3Abnormal body shapes induced by OP exposure. (A) Examples images of normal and abnormal body shapes observed in the OP-treated planarians. The normal planarian is from the vehicle controls. The contracted planarian was treated with 316 µM malathion. The remaining images are of dichlorvos-treated planarians. Scale bar: 1 mm. Inset shows magnified image of the planarian with the arrow pointing to the pharynx which is extruded from the body. (B) Stacked bar plot showing the percentage of planarians exhibiting the different body shape categories as a function of dichlorvos concentration in µM. Concentrations which are above the BMC for the outcome measure are marked with *. X indicates 100% lethality at 3.16 µM dichlorvos in adult planarians on day 12.
FIGURE 4Levels of AChE inhibition is not correlated with phenotypic effects. (A) Comparison of OP potency (measured by the most sensitive BMCadult) to AChE inhibition (IC80, blue) and hydrophobicity (logP, orange). Raw data and fitted curves from the Ellman assays are shown in Supplementary Figure S6. For acephate, the IC80 was set to the highest test concentration since no inhibition was observed. The dashed line is provided as a visual tool to show when the IC80 equals the lowest BMCadult. Blue points above this line (malathion and dichlorvos) indicate the BMC was more sensitive than the IC80. (B) A comparison of the ranking of the potency of the 7 OPs using the planarian AChE IC80 and most sensitive BMCadult.
FIGURE 5Hierarchical clustering of adult phenotypic barcodes. Active outcome measures for each chemical concentration are shown in black. Outcome measures that can have effects in both directions are separated into either the positive (+) or negative (-) direction. Only active chemical concentrations and outcome measures are shown. Numbers in chemical names refer to the respective test concentration, with 1 as the lowest tested concentration, see Table 1. Hierarchical clustering was performed using binary distance and Ward’s method. Six clusters were identified with similar phenotypic profiles: Cluster 1: Strong locomotor defects (reduced speed and increased resting), Cluster 2: effects in primarily day 7 stickiness, Cluster 3: scrunching defects only, Cluster 4: 1 or 2 hits in miscellaneous outcome measures, Cluster 5: lethal/systemic toxicity, Cluster 6: effects in scrunching and body shape with the addition of other outcomes.
FIGURE 6Hierarchical clustering of regenerating phenotypic barcodes. Active outcome measures for each chemical concentration are shown in black. Outcome measures that can have effects in both directions are separated into either the positive (+) or negative (-) direction. Only active chemical concentrations and outcome measures are shown. Numbers in chemical names refer to the respective test concentration, with 1 as the lowest tested concentration, see Table 1. Hierarchical clustering was performed using binary distance and Ward’s method. Six distinct clusters were identified with similar phenotypic profiles: Cluster 1: effects on stickiness, Cluster 2: abnormal body shapes, Cluster 3: hits in miscellaneous endpoints, Cluster 4: primarily scrunching defects, Cluster 5: effects in scrunching and body shape with the addition of other outcomes, Cluster 6: lethal/systemic toxicity.